Mogamulizumab (Anti-CCR4 / CD194), 1mg*25

Mogamulizumab (Anti-CCR4 / CD194) is a defucosylated humanized recombinant monoclonal antibody targeting CCR4. Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL). MW:145.5 KD.